These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23458425)

  • 1. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
    Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
    Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
    Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
    ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.
    Li Y; Girardi E; Wang J; Yu ED; Painter GF; Kronenberg M; Zajonc DM
    J Exp Med; 2010 Oct; 207(11):2383-93. PubMed ID: 20921281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363.
    Yu ED; Girardi E; Wang J; Mac TT; Yu KO; Van Calenbergh S; Porcelli SA; Zajonc DM
    J Biol Chem; 2012 Jan; 287(2):1269-78. PubMed ID: 22110136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
    Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
    Front Immunol; 2019; 10():2355. PubMed ID: 31649670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
    Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
    Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
    Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
    Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
    Pellicci DG; Patel O; Kjer-Nielsen L; Pang SS; Sullivan LC; Kyparissoudis K; Brooks AG; Reid HH; Gras S; Lucet IS; Koh R; Smyth MJ; Mallevaey T; Matsuda JL; Gapin L; McCluskey J; Godfrey DI; Rossjohn J
    Immunity; 2009 Jul; 31(1):47-59. PubMed ID: 19592275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,4-Dideoxy-3,3,4,4-tetrafluoro- and 4-OH epimeric 3-deoxy-3,3-difluoro-α-GalCer analogues: Synthesis and biological evaluation on human iNKT cells stimulation.
    Golten S; Patinec A; Akoumany K; Rocher J; Graton J; Jacquemin D; Le Questel JY; Tessier A; Lebreton J; Blot V; Pipelier M; Douillard JY; Le Pendu J; Linclau B; Dubreuil D
    Eur J Med Chem; 2019 Sep; 178():195-213. PubMed ID: 31185411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular basis for recognition of CD1d/α-galactosylceramide by a human non-Vα24 T cell receptor.
    López-Sagaseta J; Kung JE; Savage PB; Gumperz J; Adams EJ
    PLoS Biol; 2012; 10(10):e1001412. PubMed ID: 23109910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
    Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
    Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
    J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
    Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
    Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
    Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
    Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y
    Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
    Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
    Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
    Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
    J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding.
    Sanderson JP; Waldburger-Hauri K; Garzón D; Matulis G; Mansour S; Pumphrey NJ; Lissin N; Villiger PM; Jakobsen B; Faraldo-Gómez JD; Gadola SD
    Eur J Immunol; 2012 Jan; 42(1):248-55. PubMed ID: 21956730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.